PEDIATRICS Vol. 65 No. 3 March 1980, pp. 679
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nelson, K. B.
Right arrow Articles by Ellenberg, J. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Nelson, K. B.
Right arrow Articles by Ellenberg, J. H.

Letters to the Editor

Karin B. Nelson MD1 and Jonas H. Ellenberg PhD1

1 Development Neurology Branch, National Institute of Neurological and, Communicative Disorders and Stroke, National Institutes of Health, Federal Building, Room 8C04A, Bethesda, MD 20205

Dr Wallace is concerned that unreported treatment might have decreased the frequency of adverse outcomes observed in the NCPP after febrile seizures. The outcomes examined were death, motor deficit, epilepsy, intellectual impairment, poor early scholastic achievement, and recurrences of febrile seizures. To the best of our knowledge, there is no evidence that treatment of febrile seizures can alter the frequency of any of these outcomes except recurrences. Furthermore, in studies performed without monitoring of blood levels of anticonvulsants, compliance was apparently so poor that there was no effect of treatment even on recurrence rate.1,2